Intra-Cellular Therapies ITCI 深 沪
等待开盘 04-01 09:30:00 美东时间
131.87
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 131.87
- 总市值 141.10亿
- 52周最高 131.98
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 64.09
- 委 比 0.00%
- 总股本 1.07亿
- 历史最高 131.98
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.75
- 每 手 1
- 风险率 0.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Johnson & Johnson publishes 2025 annual report with USD 94.2 billion sales
Johnson & Johnson publishes 2025 annual report with USD 94.2 billion sales Johnson & Johnson published its 2025 annual report, outlining increased focus on six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. The company reported 5% operational sales growth in
03-11 21:23
1430亿美元，全球创新药并购重回高峰
经历2024年生科寒冬之后，2025年全球并购强势回暖，交易规模再度突破千亿美元大关，直逼2023年水平。 医药魔方MedAlpha新药投融资数据库显示，20...
01-27 16:14
JPM2026观察：超百亿巨额并购降温、AI投资热情飙升，中国药企变“台上主角”
每年年初的摩根大通全球医疗健康（JPM）大会，对于全球生物医药行业从业者而言，不只是巨头晾晒成绩单与战略蓝图的秀场，也像是决定未来一年甚至更长时间里资本流向与产...
01-26 16:12
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Benitec Biopharma Inc. announced positive interim results for its BB-301 Phase 1b/2a clinical trial treating oculopharyngeal muscular dystrophy (OPMD) with dysphagia. All six patients in Cohort 1 achieved a 100% response rate, showing significant improvements in dysphagic symptoms, swallowing function, and reduced post-swallow residue. The U.S. FDA granted Fast Track designation to BB-301, recognizing the urgency of its potential for treating thi...
2025-11-03 12:10
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Benitec Biopharma Inc. announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates, a seasoned biotech leader, previously co-founded and led Intra-Cellular Therapies, which was acquired by Johnson & Johnson for $14.6 billion. She joins Benitec as it advances its BB-301 gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD) and expands its ddRNAi platform. The company’s “Silence and Replace” technology combines RNA inter...
2025-11-03 12:00
诺华宣布将以约120亿美元收购美国生物科技公司
（来源：欧洲并购与投资） 诺华宣布将以约120亿美元收购美国生物科技公司 图片来源：iStock 在强生以146亿美元收购Intra-Cellula...
2025-10-27 16:29
BREAKINGVIEWS-J&J slims down but struggles to get fit
The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 14 (Reuters Breakingviews) - Slimming down is all the rage, and Johnson & Johnson JNJ...
2025-10-14 23:45
强生洽谈收购估值超40亿美元的生物科技公司
（来源：欧洲并购与投资） 强生洽谈收购估值超40亿美元的生物科技公司 图片来源：dpa 据媒体报道，强生公司正在就收购生物科技公司Protagoni...
2025-10-13 11:35
BREAKINGVIEWS-Big Pharma has rare shot at bargain hunting
The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan DUBLIN, Aug 11 (Reuters Breakingviews) - Big Pharma has a big problem. GSK GSK.L, Pfizer PFE.N a...
2025-08-11 17:49
